US Pharma MarketingSobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III
Innate is planning to begin a Phase III confirmatory trial on lacutamab as it vies for the drug’s accelerated approval in a rare CTCL subset.
Innate is planning to begin a Phase III confirmatory trial on lacutamab as it vies for the drug’s accelerated approval in a rare CTCL subset.
Source: Pharmaceutical Technology